HK1212213A1 - Formulation comprising benzothiazolone compound - Google Patents

Formulation comprising benzothiazolone compound

Info

Publication number
HK1212213A1
HK1212213A1 HK16100094.7A HK16100094A HK1212213A1 HK 1212213 A1 HK1212213 A1 HK 1212213A1 HK 16100094 A HK16100094 A HK 16100094A HK 1212213 A1 HK1212213 A1 HK 1212213A1
Authority
HK
Hong Kong
Prior art keywords
formulation
benzothiazolone compound
benzothiazolone
compound
Prior art date
Application number
HK16100094.7A
Other languages
English (en)
Chinese (zh)
Inventor
Miloud Achour
Robin Alec Fairhurst
Arnaud Grandeury
Shinji Hatakeyama
Magdalena Koziczak-Holbro
Nicola Tufilli
Thomas Ullrich
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1212213A1 publication Critical patent/HK1212213A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK16100094.7A 2013-02-28 2016-01-06 Formulation comprising benzothiazolone compound HK1212213A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361770584P 2013-02-28 2013-02-28
PCT/IB2014/059270 WO2014132205A1 (en) 2013-02-28 2014-02-26 Formulation comprising benzothiazolone compound

Publications (1)

Publication Number Publication Date
HK1212213A1 true HK1212213A1 (en) 2016-06-10

Family

ID=50238437

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16100094.7A HK1212213A1 (en) 2013-02-28 2016-01-06 Formulation comprising benzothiazolone compound

Country Status (31)

Country Link
US (1) US9623012B2 (sl)
EP (1) EP2961391B1 (sl)
JP (2) JP6230626B2 (sl)
KR (1) KR20150120386A (sl)
CN (1) CN104968337A (sl)
AU (1) AU2014222362B2 (sl)
BR (1) BR112015020059A2 (sl)
CA (1) CA2897565A1 (sl)
CL (1) CL2015001940A1 (sl)
CY (1) CY1119202T1 (sl)
DK (1) DK2961391T3 (sl)
EA (1) EA026914B1 (sl)
ES (1) ES2637802T3 (sl)
HK (1) HK1212213A1 (sl)
HR (1) HRP20171177T1 (sl)
HU (1) HUE034353T2 (sl)
IL (1) IL240495A0 (sl)
LT (1) LT2961391T (sl)
MA (1) MA38354B1 (sl)
MX (1) MX2015011290A (sl)
NZ (1) NZ709747A (sl)
PE (1) PE20151608A1 (sl)
PH (1) PH12015501701A1 (sl)
PL (1) PL2961391T3 (sl)
PT (1) PT2961391T (sl)
SA (1) SA515360952B1 (sl)
SG (1) SG11201505544RA (sl)
SI (1) SI2961391T1 (sl)
TN (1) TN2015000310A1 (sl)
WO (1) WO2014132205A1 (sl)
ZA (1) ZA201504863B (sl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3192B1 (ar) 2011-09-06 2018-03-08 Novartis Ag مركب بنزوثيازولون
HUE033655T2 (en) * 2012-08-30 2017-12-28 Novartis Ag Benzothiazolone Compounds with Beta-2-Adrenoceptor Effects
PL2961391T3 (pl) * 2013-02-28 2017-10-31 Novartis Ag Preparat zawierający pochodną benzotiazolonu

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR040962A1 (es) * 2002-08-09 2005-04-27 Novartis Ag Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2005110990A1 (de) 2004-05-13 2005-11-24 Boehringer Ingelheim International Gmbh Hydroxy-substituierte benzkondensierte heterozyklen als betaagonisten zur behandlung von atemwegserkrankungen
GB0426164D0 (en) * 2004-11-29 2004-12-29 Novartis Ag Organic compounds
DE102009003975A1 (de) * 2009-01-07 2010-07-08 Merck Patent Gmbh Benzothiazolonderivate
JO3192B1 (ar) * 2011-09-06 2018-03-08 Novartis Ag مركب بنزوثيازولون
PL2961391T3 (pl) * 2013-02-28 2017-10-31 Novartis Ag Preparat zawierający pochodną benzotiazolonu

Also Published As

Publication number Publication date
SA515360952B1 (ar) 2016-07-10
PE20151608A1 (es) 2015-11-19
JP2016510020A (ja) 2016-04-04
SI2961391T1 (sl) 2017-08-31
IL240495A0 (en) 2015-09-24
US20160000761A1 (en) 2016-01-07
PH12015501701A1 (en) 2015-10-12
KR20150120386A (ko) 2015-10-27
ZA201504863B (en) 2016-06-29
CL2015001940A1 (es) 2015-10-30
LT2961391T (lt) 2017-07-25
CA2897565A1 (en) 2014-09-04
EP2961391B1 (en) 2017-05-17
JP6230626B2 (ja) 2017-11-15
JP2018035186A (ja) 2018-03-08
EA026914B1 (ru) 2017-05-31
AU2014222362B2 (en) 2016-07-21
TN2015000310A1 (en) 2017-01-03
CY1119202T1 (el) 2018-02-14
WO2014132205A1 (en) 2014-09-04
PL2961391T3 (pl) 2017-10-31
EP2961391A1 (en) 2016-01-06
US9623012B2 (en) 2017-04-18
ES2637802T3 (es) 2017-10-17
HRP20171177T1 (hr) 2017-10-06
DK2961391T3 (en) 2017-09-04
MX2015011290A (es) 2015-12-03
SG11201505544RA (en) 2015-09-29
MA38354B1 (fr) 2016-09-30
EA201591577A1 (ru) 2015-12-30
CN104968337A (zh) 2015-10-07
AU2014222362A1 (en) 2015-07-23
PT2961391T (pt) 2017-08-29
HUE034353T2 (en) 2018-02-28
NZ709747A (en) 2018-04-27
BR112015020059A2 (pt) 2017-07-18
MA38354A1 (fr) 2016-02-29

Similar Documents

Publication Publication Date Title
IL249518B (en) A compound that inhibits trk
AP2015008713A0 (en) Tetrahydropyrrolothiazine compounds
GB201302368D0 (en) Compound
EP2968569A4 (en) COUGAR FORMULATION
HK1219100A1 (zh) 吡啶基吡唑並喹啉化合物
EP2970924A4 (en) PHYTASEFORMULIERUNG
AP3850A (en) Azetidinyloxyphenylpyrrolidine compounds
GB201320432D0 (en) Novel formulation
EP2947066A4 (en) PHENOXYALKYLAMINVERBINDUNG
GB201322948D0 (en) Improved formulation
HK1212213A1 (en) Formulation comprising benzothiazolone compound
GB2517232B (en) Formulation
EP2948457A4 (en) COMPOUNDS
GB201317718D0 (en) Novel formulation
GB201307331D0 (en) Compound
GB201408643D0 (en) Compound
HK1209981A1 (en) Formulation
GB201312347D0 (en) Formulation
GB201317717D0 (en) Novel formulation
GB201322438D0 (en) Compound
GB201315772D0 (en) Compound
GB201305634D0 (en) Compound
GB201304250D0 (en) Compound
GB201301585D0 (en) Compound

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210225